ESR1 and breast carcinoma: Firstly, Johnson et al. [54] showed that D1 receptor agonist SKF38393 reduced the viability of growth-inducted MCF7 ER-positive breast cancer cell line stronger than tamoxifen (selective estrogen receptor modulator used in the treatment of breast cancer).